Table 1 Therapeutics targeting inhibitory immune checkpoints and co-stimulatory molecules

From: Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Basic information					Representative trial
Target	Agent	Manufacturer	Agent type	Highest developmental phase	Phase	Cancer type	Therapeutic combination	Study	Identifier	Status
Additional inhibitory checkpoints
LAG-3 pathway
LAG-3	Relatlimab (BMS-986016)	Bristol-Myers Squibb	Antagonistic mAb	FDA approved	III	Melanoma	Anti-PD-1 (Nivolumab)	RELATIVITY-047	NCT03470922	Active, not recruiting
	Miptenalimab (BI 754111)	Boehringer Ingelheim	Antagonistic mAb	II	II	Solid Tumors	anti-PD-1 (Ezabenlimab), VEGF/Ang2 inhibitor (BI 836880)		NCT03697304	Recruiting
	Favezelimab (MK4280)	Merck Sharp & Dohme	Antagonistic mAb	III	III	CRC	Anti-PD-1 (Pembrolizumab)	MK-4280A-007	NCT04938817	Not yet recruiting
	Fianlimab (REGN3767)	Regeneron	Antagonistic mAb	II	II	Breast Cancer	Anti-PD-1 (Cemiplimab)	I-SPY	NCT01042379	Recruiting
	Leramilimab (LAG525, IMP-701)	Immutep Limited, Novartis	Antagonistic mAb	II	II	Breast Cancer	Anti-PD-1 (Spartalizumab), chemotherapy		NCT03499899	Active, not recruiting
	Encelimab (TSR-033)	AnaptysBio, GlaxoSmithKline	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Dostarlimab), chemotherapy	CITRINO	NCT03250832	Active, not recruiting
	Sym 022	Symphogen	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Sym021), anti-TIM-3 (Sym023)		NCT03311412	Recruiting
	IBI-110	Innovent Biologics	Antagonistic mAb	II	II	SCLC	Anti-PD-1 (Sintilimab), chemotherapy		NCT05026593	Recruiting
	INCAGN02385/INCAGN 2385	Agenus	Antagonistic mAb	I/II	I/II	Melanoma	Anti-PD-1 (INCMGA00012), anti-TIM-3 (INCAGN02390)		NCT04370704	Recruiting
	SHR-1802	Jiangsu Hengrui	Antagonistic mAb	I	I	Malignancies	–		NCT04414150	Recruiting
	LBL-007	Leads Biolabs	Antagonistic mAb	I	I	Melanoma	Anti-PD-1 (Toripalimab)		NCT04640545	Recruiting
	Eftilagimod alpha (IMP 321)	Immutep/Merck & Co	LAG-3-Ig fusion protein	II	II	NSCLC, HNSCC	Anti-PD-1 (Pembrolizumab)	TACTI-002	NCT03625323	Recruiting
TIM-3 pathway
TIM-3	Cobolimab (TSR-022)	AnaptysBio/Glaxo SmithKline	Antagonistic mAb	II	II	NSCLC	Anti-PD-1 (Dostarlimab), chemotherapy	COSTAR Lung	NCT04655976	Recruiting
	Sabatolimab (MBG-453)	Novartis	Antagonistic mAb	III	III	MDS, CMML	Chemotherapy	STIMULUS-MDS2	NCT04266301	Recruiting
	INCAGN2390	Agenus	Antagonistic mAb	I/II	I/II	Melanoma	Anti-PD-1 (Retifanlimab/INCMGA00012), anti-LAG-3 (INCAGN02385/INCAGN 2385)		NCT04370704	Recruiting
	BGB-A425	BeiGene	Antagonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1 (Tislelizumab)		NCT03744468	Recruiting
	SHR-1702	Jiangsu Hengrui	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Camrelizumab)		NCT03871855	Not yet recruiting
	LY3321367	Eli Lilly and Company	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-L1 (LY3300054)	PACT	NCT02791334	Active, not recruiting
	Sym023	Symphogen	Antagonistic mAb	I	I	BTC	Anti-PD-1 (Sym021), anti-LAG-3 (INCAGN02385/INCAGN 2385)		NCT04641871	Active, not recruiting
	BMS-986258	Bristol-Myers Squibb	Antagonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1 (Nivolumab), Recombinant human hyaluronidase (rHuPH20)		NCT03446040	Recruiting
CEACAM-1	CM24	Purple Biotech, Bristol-Myers Squibb	Antagonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1 (Nivolumab), chemotherapy		NCT04731467	Recruiting
galecting-9	LYT-200	PureTech	Antagonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1, chemotherapy		NCT04666688	Recruiting
TIGIT pathway
TIGIT	Vibostolimab (MK-7684)	Merck Sharp & Dohme	Antagonistic mAb	III	III	NSCLC	Anti-PD-1 (Pembrolizumab)	MK-7684A-003	NCT04738487	Recruiting
	Tiragolumab (MTIG-7192A)	Genentech, Roche	Antagonistic mAb	III	III	NSCLC	Anti-PD-1 (Atezolizumab)	SKYSCRAPER-01	NCT04294810	Recruiting
	Ociperlimab (BGB-A1217)	BeiGene	Antagonistic mAb	III	III	NSCLC	Anti-PD-1 (Tislelizumab), chemotherapy	AdvanTIG-301	NCT04866017	Recruiting
	Etigilimab (OMP-313M32)	Mereo BioPharma, OncoMed	Antagonistic mAb	II	II	Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer	Anti-PD-1 (Nivolumab)	EON	NCT05026606	Recruiting
	BMS-986207	Bristol-Myers Squibb, Compugen	Antagonistic mAb	II	I/II	Solid Tumors	Anti-PD-1 (Nivolumab), anti-CD112R (COM701)		NCT04570839	Recruiting
	Domvanalimab (AB154)	Arcus Biosciences	Antagonistic mAb	III	III	NSCLC	Anti-PD-1 (Zimberelimab/AB122)	ARC-10	NCT04736173	Recruiting
	SEA-TGT (SGN-TGT)	Seattle Genetics, Seagen	Antagonistic mAb	I/II	I/II	NSCLC	Anti-PD-1 (Sasanlimab), VEGFR1/2/3 TKI (Axitinib)		NCT04585815	Recruiting
	IBI-939	Innovent Biologics	Antagonistic mAb	I	I	NSCLC	Anti-PD-1 (Sintilimab)		NCT04672369	Not yet recruiting
	JS006	Shanghai Junshi	Antagonistic mAb	I	I	Malignancies	Anti-PD-1 (Toripalimab)		NCT05061628	Recruiting
	AK127	Akeso Biopharma	Antagonistic mAb	I	I	Solid Tumors	PD-1 x CTLA-4 bsAb (AK104)		NCT05021120	Not yet recruiting
CD155	PVSRIPO (Lerapolturev)	Istari Oncology, Duke University Medical Center	Recombinant polio virus (act by biology of CD155)	II	II	Glioblastoma	Anti-PD-1 (Pembrolizumab)	LUMINOS-101	NCT04479241	Active, not recruiting
	EOS884448 (EOS-448, GSK-4428859)	iTeos Therapeutics	Antagonistic mAb	II	II	NSCLC	Anti-PD-1 (Dostarlimab)		NCT03739710	Recruiting
CD96	GSK6097608	GlaxoSmithKline	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Dostarlimab)		NCT04446351	Recruiting
CD112R	COM701 (CGEN-15029)	Compugen	Antagonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1 (Nivolumab), anti-TIGIT (BMS-986207)		NCT04570839	Recruiting
Nectin-4	Enfortumab Vedotin	Astellas, Merck & Co, Seagen	ADC	III	III	Ureteral Cancer	–	EV-301	NCT03474107	Active, not recruiting
	BT8009	Bicycle Therapeutics	Bicycle toxin conjugate	I/II	I/II	Solid Tumorss	Anti-PD-1(Nivolumab)		NCT04561362	Recruiting
CD47-SIRPα pathway
CD47	Magrolimab (Hu5F9-G4)	Gilead	Antagonistic mAb	III	III	AML	Chemotherapy	ENHANCE-3	NCT05079230	Active, not recruiting
	Lemzoparlimab (TJ011133, TJC4)	I-Mab Biopharma	Antagonistic mAb	III	III	MDS	Chemotherapy		NCT05709093	Recruiting
	Ligufalimab (AK117)	Akeso	Antagonistic mAb	II	I/II	Malignancies	Anti-PD-1/VEGF (AK112), chemotherapy		NCT05229497	Recruiting
	Letaplimab (IBI188)	Innovent Biologics (Suzhou) Co. Ltd.	Antagonistic mAb	I	I	Malignancies	–		NCT03763149	Completed
	Urabrelimab (SRF231)	Surface Oncology	Antagonistic mAb	I	I	Malignancies	–		NCT03512340	Completed
	ZL-1201	Zai Lab (Shanghai) Co., Ltd.	Antagonistic mAb	I	I	Advanced Cancer	–		NCT04257617	Completed
	AO-176	Arch Oncology	Antagonistic mAb	I/II	I/II	Ovarian Cancer	Anti-PD-1 (Pembrolizumab), chemotherapy	KEYNOTE-C49	NCT03834948	Completed
	STI-6643	Sorrento Therapeutics, Inc.	Antagonistic mAb	I	I	Solid Tumors	–		NCT04900519	Recruiting
	CC-90002	Celgene	Antagonistic mAb	I	I	Malignancies	Anti-CD20 (Rituximab)		NCT02367196	Completed
	Evorpacept (ALX148)	ALX Oncology Inc.	Anti-CD47-Fc fusion protein	II/III	II/III	GC, GEJC	Anti-HER2 (Trastuzumab), anti-EGFR (Ramucirumab), chemotherapy	ASPEN-06	NCT05002127	Recruiting
	Maplirpacept (TTI-622, PF-07901801)	Pfizer	Anti-CD47-Fc fusion protein	II	I/II	DLBCL	Anti-CD19 (Tafasitamab), Lenalidomide		NCT05626322	Recruiting
	Nibrozetone (RRx-001)	EpicentRx, Inc.	Small molecule MYC and CD47 downregulator	III	III	SCLC	Chemotherapy	REPLATINUM	NCT05566041	Active, not recruiting
SIRPα	BI 765063 (OSE-172)	Boehringer Ingelheim	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (BI 754091)		NCT03990233	Active, not recruiting
	Ontorpacept (TTI-621)	Pfizer	SIRPα-Fc fusion protein	II	II	DLBCL	Anti-PD-1 (Pembrolizumab)		NCT05507541	Recruiting
	DSP107	Kahr Medical	SIRPα-4-1BBL bifunctional fusion protein	I/II	I/II	Solid Tumors	Anti-PD-L1 (Atezolizumab)		NCT04440735	Recruiting
	IMM01	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	SIRPα-Fc fusion protein	I/II	I/II	AML, MDS	Azacitidine		NCT05140811	Recruiting
	IMM0306	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	SIRPα-anti-CD20 fusion protein	I/II	I/II	B-cell NHL	Lenalidomide		NCT05771883	Not yet recruiting
B7 family proteins
B7-H3	MGC018	MacroGenics	ADC	I/II	I/II	Solid tumors	Anti-PD-1 (Retifanlimab)		NCT03729596	Recruiting
	mirzotamab clezutoclax (ABBV-155)	AbbVie	ADC	I	I	Solid tumors	Chemotherapy		NCT03595059	Recruiting
	DS-7300a	Daiichi Sankyo	ADC	I/II	I/II	Solid tumors	–		NCT04145622	Recruiting
B7-H4	Alsevalimab (FPA-150)	Amgen, Five Prime Therapeutics	Antagonistic mAb	I	I	Solid tumors	Anti-PD-1 (Pembrolizumab)	FPA150-001	NCT03514121	Completed
	NC762	NextCure	Antagonistic mAb	I/II	I/II	Solid tumors	–		NCT04875806	Recruiting
B7-H5	HMBD-002	Hummingbird Bioscience	Antagonistic mAb	I	I	Solid tumors	Anti-PD-1 (Pembrolizumab)		NCT05082610	Recruiting
	Onvatilimab (JNJ-61610588, CI-8993, VSTB112)	Curis, Janssen, ImmuNext	Antagonistic mAb	I	I	Solid tumors	–		NCT04475523	Recruiting
	CA-170	Aurigene Discovery Technologies	Small molecule inhibitor	II	II	Solid tumors and lymphomas			CTRI/2017/12/011026	Completed
Co-stimulatory molecules
ICOS	Vopratelimab (JTX-2011)	Jounce Therapeutics	Agonistic mAb	II	II	NSCLC	Anti-PD-1 (Pimivalimab, JTX-4014)	SELECT	NCT04549025	Active, not recruiting
	Alomfilimab (KY1044, SAR-445256)	Kymab, Sanofi	Agonistic mAb	I/II	I/II	Solid Tumors	Anti-PD-1 (Atezolizumab)		NCT03829501	Recruiting
CD40	SEA-CD40	Seagen, Merck Sharp & Dohme	Agonistic mAb	II	I	Solid Tumors	Anti-PD-1 (Pembrolizumab), chemotherapy	SGNS40-001	NCT02376699	Active, not recruiting
	Mitazalimab (Vanalimab, ADC-1013, JNJ-64457107)	Alligator Bioscience, Janssen	Agonistic mAb	I/II	I/II	PDAC	Chemotherapy	OPTIMIZE-1	NCT04888312	Enrolling by invitation
	Sotigalimab (APX005M)	Apexigen, Bristol-Myers Squibb	Agonistic mAb	II	I/II	PDAC	Anti-PD-1 (Nivolumab), anti-CSF1R (Cabiralizumab)	PRINCE, PICI0002	NCT03214250	Active, not recruiting
	Giloralimab (ABBV-927)	AbbVie	Agonistic mAb	II	II	Pancreatic Cancer	Anti-PD-1 (Budigalimab), chemotherapy		NCT04807972	Recruiting
	YH003	Eucure Biopharma	Agonistic mAb	II	II	Melanoma, PDAC	Anti-PD-1 (Toripalimab), chemotherapy		NCT05031494	Recruiting
	CDX-1140	Celldex Therapeutics	Agonistic mAb	II	II	Ovarian Cancer	Anti-PD-1 (Pembrolizumab), anti-VEGF (Bevacizumab), chemotherapy		NCT05231122	Not yet recruiting
OX40	Revdofilimab (ABBV-368)	Abbvie	Agonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Budigalimab), anti-CTLA-4 (Ipilimumab)		NCT04196283	Active, not recruiting
	HFB301001	HiFiBiO Therapeutics	Agonistic mAb	I	I	Solid Tumors			NCT05229601	Recruiting
	BGB-A445	BeiGene	Agonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Tislelizumab)		NCT04215978	Recruiting
4-1BB/CD137	ADG106	Adagene	Agonistic mAb	I/II	I/II	NSCLC	Anti-PD-1 (Nivolumab)	ADIVO Lung	NCT05236608	Recruiting
	LVGN6051	Lyvgen Biopharma	Agonistic mAb	I/II	I/II	Soft Tissue Sarcoma	TKI (Anlotinib)		NCT05301764	Not yet recruiting
	AGEN2373	Agenus	Agonistic mAb	I	I	Solid Tumors	Anti-CTLA-4 (AGEN1181)		NCT04121676	Recruiting
	ATOR1017	Alligator Bioscience	Agonistic mAb	I	I	Solid Tumors			NCT04144842	Recruiting
Anti-PD-1/PD-L1 and anti-CTLA-4 agents
PD-1	Pembrolizumab	Merck	Antagonistic mAb	FDA approved	I	Solid tumors	–	KEYNOTE-001	NCT01295827	Completed
	Nivolumab	Bristol-Myers Squibb	Antagonistic mAb	FDA approved	III	NSCLC	–	CheckMate 017	NCT01642004	Completed
	Dostarlimab	GlaxoSmithKline	Antagonistic mAb	FDA approved	I	Solid tumors	–	GARNET	NCT02715284	Recruiting
	Cemiplimab	Regeneron	Antagonistic mAb	FDA approved	III	NSCLC	–	EMPOWER-Lung 1	NCT03088540	Active, not recruiting
	Toripalimab (JS001)	Shanghai Junshi Biosciences	Antagonistic mAb	III	III	NSCLC	Chemotherapy		NCT04158440	Recruiting
	Sintilimab (IBI308)	Eli Lilly /Innovent Biologics	Antagonistic mAb	III	III	HCC	Anti-VEGF (Bevacizumab)	DaDaLi	NCT04682210	Not yet recruiting
	Tislelizumab (BGB-A317)	BeiGene	Antagonistic mAb	IV	IV	NMIBC	Cancer vaccine (BCG)		NCT05580354	Not yet recruiting
	Camrelizumab (SHR-1210)	Jiangsu Hengrui	Antagonistic mAb	III	III	NSCLC	TKI (Famitinib)		NCT05042375	Recruiting
	Pucotenlimab (HX008)	Taizhou Hanzhong Pharmaceuticals	Antagonistic mAb	III	III	GC	Chemotherapy		NCT04486651	Recruiting
	Serplulimab (HLX10)	Shanghai Henlius	Antagonistic mAb	III	III	NSCLC	Anti-VEGF (HLX04), chemotherapy		NCT03952403	Recruiting
	Budigalimab (ABBV-181)	AbbVie	Antagonistic mAb	II	II	Pancreatic Cancer	Anti-CD40 (ABBV-927), chemotherapy		NCT04807972	Recruiting
	Retifanlimab (INCMGA00012)	Incyte Corporation/Macrogenics	Antagonistic mAb	III	III	NSCLC	Chemotherapy	POD1UM-304	NCT04205812	Recruiting
	Ezabenlimab (BI 754091)	Boehringer Ingelheim	Antagonistic mAb	II	II	Solid Tumors	VEGF/ANG2 inhibitor (BI 836880), anti-LAG-3 (BI 754111)		NCT03697304	Active, not recruiting
	Penpulimab (AK105)	Akeso Biopharma/Chia Tai Tianqing	Antagonistic mAb	IV	IV	NSCLC	TKI (Anlotinib)	pcwaintrl	NCT05387109	Not yet recruiting
	Spartalizumab (PDR001)	Novartis	Antagonistic mAb	III	III	Melanoma	Braf inhibitor (Dabrafenib), MAP1/2 inhibitor (Trametinib)	COMBI-i	NCT02967692	Active, not recruiting
	Cetrelimab (JNJ-63723283)	Janssen	Antagonistic mAb	III	III	MIBC	Chemotherapy	SunRISe-2	NCT04658862	Recruiting
	Balstilimab (AGEN2034)	Agenus	Antagonistic mAb	II	II	CRC	Anti-CTLA-4 (Botensilimab)	NEST-1	NCT05571293	Not yet recruiting
	Zimberelimab (GLS-010)	Arcus/Guangzhou Gloria/Taiho Pharmaceutical	Antagonistic mAb	III	III	NSCLC	Anti-TIGIT (Domvanalimab), chemotherapy	ARC-10	NCT04736173	Recruiting
	Geptanolimab (Genolimzumab, APL 501)	Apollomics	Antagonistic mAb	II	II	Cervical Cancer	–		NCT03808857	Recruiting
	Prolgolimab (BCD-100)	Biocad	Antagonistic mAb	III	III	Cervical Cancer	Anti-EGFR (Bevacizumab), chemotherapy	FERMATA	NCT03912415	Recruiting
	Sasanlimab (PF-06801591)	Pfizer	Antagonistic mAb	III	III	NMIBC	Cancer vaccine (BCG)	CREST	NCT04165317	Recruiting
	Cosibelimab	Checkpoint Therapeutics/TG Therapeutics	Antagonistic mAb	III	III	NSCLC	Chemotherapy	CONTERNO	NCT04786964	Active, not recruiting
	Pimivalimab (JTX-4014)	Celgene, Jounce Therapeutics	Antagonistic mAb	II	II	NSCLC	ICOS agonist (Vopratelimab)	SELECT	NCT04549025	Active, not recruiting
	MEDI0680 (AMP514)	Amplimmune; AstraZeneca; MedImmune	Antagonistic mAb	I/II	I/II	Malignancies	Anti-PD-L1 (Durvalumab)		NCT02118337	Completed
	Nofazinlimab (CS1003)	CStone Pharmaceuticals	Antagonistic mAb	III	III	HCC	TKI (Lenvatinib)		NCT04194775	Recruiting
PD-L1	Atezolizumab	Roche, Genentech	Antagonistic mAb	FDA approved	III	NSCLC	–	OAK	NCT02008227	Completed
	Durvalumab	Celgene, MedImmune	Antagonistic mAb	FDA approved	III	NSCLC	–	PACIFIC	NCT02125461	Active, not recruiting
	Avelumab	Merck	Antagonistic mAb	FDA approved	II	MCC	–	JAVELIN Merkel 200	NCT02155647	Active, not recruiting
	Pacmilimab (CX-072)	CytomX Therapeutics	Probody	II	II	Breast Cancer	ADC (CX-2009)		NCT04596150	Active, not recruiting
	Sugemalimab (CS1001)	CStone Pharmaceuticals, Bayer	Antagonistic mAb	III	III	NSCLC	–	GEMSTONE-301	NCT03728556	Active, not recruiting
	Opucolimab (HLX-20)	Henlix Biotech	Antagonistic mAb	I	I	Solid Tumors	–		NCT03588650	Completed
	Envafolimab (KN035)	Alphamab	Antagonistic mAb	III	III	Biliary Tract Cancer	chemotherapy	KN035-BTC	NCT03478488	Recruiting
	Adebrelimab (SHR-1316)	Atridia; Jiangsu Hengrui	Antagonistic mAb	III	III	NSCLC	chemotherapy		NCT04316364	Recruiting
	INCB86550	Incyte Corporation	Small molecule inhibitor	II	II	Solid Tumors	–		NCT04629339	Active, not recruiting
	MAX-10181	Maxinovel Pharmaceuticals	Small molecule inhibitor	I	I	Solid Tumors	–		NCT05196360	Recruiting
CTLA-4	Ipilimumab	Bristol-Myers Squibb	Antagonistic mAb	FDA approved	III	NSCLC	Anti-PD-1 (Nivolumab), chemotherapy	CHECKMATE-227	NCT02477826	Active, not recruiting
	Tremelimumab	Pfizer, AstraZeneca	Antagonistic mAb	FDA approved	III	HCC	Anti-PD-L1 (Durvalumab)	HIMALAYA	NCT03298451	Recruiting
	BMS-986249	Bristol-Myers Squibb	Probody	I/II	I/II	Solid Tumors	Anti-PD-1 (Nivolumab)		NCT03369223	Recruiting
	Botensilimab (AGEN-1811)	Agenus	Antagonistic mAb	II	II	CRC	Anti-PD-1 (Balstilimab)	NEST-1	NCT05571293	Not yet recruiting
	Zalifrelimab (AGEN1884)	Agenus	Antagonistic mAb	II	II	Cervical Cancer	Anti-PD-1 (Balstilimab)		NCT05033132	Recruiting
	Quavonlimab (MK-1308)	Merck Sharp & Dohme	Antagonistic mAb	III	III	RCC	TKI (Lenvatinib), anti-PD-1 (Pembrolizumab)		NCT04736706	Recruiting
	Porustobart (HBM-4003)	Harbour BioMed	Antagonistic mAb	I	I	Solid Tumors	Anti-PD-1 (Triprilimab)		NCT04727164	Not yet recruiting
	YH-001	Eucure Biopharma	Antagonistic mAb	II	II	HCC, NSCLC	Anti-PD-1 (Toripalimab)		NCT05212922	Not yet recruiting
	ADG-116	Adagene	Antagonistic mAb	I	I	Solid Tumors	Anti-PD1 mAb, CD137 agonist (ADG106)		NCT04501276	Recruiting
	ONC-392	OncoImmune	Antagonistic mAb	II	II	Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer	Anti-PD-1 (Pembrolizumab)	PRESERVE-004	NCT05446298	Not yet recruiting

The data are up to December 2022. For each agent, only one representative clinical trial is listed. All ongoing clinical trials for each agent are listed in Supplementary Tables 1–3. The therapeutic combination described in the representative trial is a simplified summary. For each drug, the cases of all kinds of combinations of the drug and other agents in one or several cohorts in a multi-cohort study, or the combination of the drug and other agents in a mono-cohort study are not separately described
mAb monoclonal antibody, FDA Food and Drug Administration, NSCLC non-small cell lung cancer, HCC hepatocellular carcinoma, NMIBC non-muscle-invasive bladder cancer, BCG bacillus Calmette-Guérin, GC gastric cancer, CRC colorectal cancer, MCC Merkel cell carcinoma, RCC renal cell carcinoma, SCLC small-cell lung cancer, HNSCC head and neck squamous cell carcinoma, AML acute myeloid leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, GEJC gastroesophageal junction cancer, DLBCL diffuse large B cell lymphoma, NHL non-Hodgkin’s lymphoma, BTC biliary tract cancer, ADC antibody-drug conjugate, PDAC pancreatic ductal adenocarcinoma, TKI tyrosine kinase inhibitors

Back to article page

Table 1 Therapeutics targeting inhibitory immune checkpoints and co-stimulatory molecules

Search

Quick links